<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075240</url>
  </required_header>
  <id_info>
    <org_study_id>EPCATIII.001</org_study_id>
    <nct_id>NCT04075240</nct_id>
  </id_info>
  <brief_title>VTE Prevention Following Total Hip and Knee Arthroplasty</brief_title>
  <acronym>EPCATIII</acronym>
  <official_title>Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban and Aspirin to Aspirin Alone Following Total Hip and Knee Arthroplasty (EPCATIII)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sudeep Shivakumar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Consented patients undergoing elective total hip and total knee arthroplasty will be
      randomized to receive either aspirin alone or aspirin and rivaroxaban for prevention of
      venous thromboembolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aspirin and rivaroxaban prevent venous thromboembolism (VTE) via different mechanisms.
      Aspirin is significantly cheaper than rivaroxaban. Aspirin in combination with rivaroxaban
      was shown to be safe and efficacious in a non-inferiority trial (EPCATII) when compared to
      rivaroxaban alone.

      This study will assess if aspirin alone is non-inferior to rivaroxaban and aspirin in the
      prevention of venous thromboembolism.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>randomized, controlled, double-blind</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>over-encapsulated rivaroxaban/ASA</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolism</measure>
    <time_frame>90 days</time_frame>
    <description>symptomatic proximal deep vein thrombosis or pulmonary embolism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding</measure>
    <time_frame>90 days</time_frame>
    <description>major and clinically relevant, non-major bleeds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>90 days</time_frame>
    <description>all cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>90 days</time_frame>
    <description>quantitatively describe the costs of symptomatic thromboembolism events and major bleeding episodes</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">5400</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>THA-control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total Hip Arthroplasty: 5 days of rivaroxaban, followed by 30 days of aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THA-study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total Hip Arthroplasty: 35 days of aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TKA-control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total Knee Arthroplasty: 5 days of rivaroxaban, followed by 9 days of aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TKA-study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total Knee Arthroplasty: 14 days of aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 10 MG and acetylsalicylic acid 81 mg</intervention_name>
    <description>Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)</description>
    <arm_group_label>THA-control arm</arm_group_label>
    <arm_group_label>TKA-control arm</arm_group_label>
    <other_name>Xarelto 10mg and aspirin 81mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid 81 mg</intervention_name>
    <description>Starting post op, aspirin for 9 days for TKA and 30 days for THA</description>
    <arm_group_label>THA-study arm</arm_group_label>
    <arm_group_label>TKA-study arm</arm_group_label>
    <other_name>aspirin 81mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients undergoing elective THA/TKA at the participating institutions will be
             potentially eligible for this study

          2. Written informed consent in accordance with federal, local and institutional
             guidelines

        Exclusion Criteria:

          1. Previous documented VTE (proximal DVT or any PE)

          2. Hip or lower limb fracture in the previous three months, not related to present
             surgery

          3. Metastatic cancer

          4. Life expectancy less than 6 months

          5. History of major bleeding that in the judgment of the investigator precludes use of
             anticoagulant prophylaxis

          6. History of aspirin allergy, active peptic ulcer disease or gastritis that in the
             judgment of investigator precludes use of aspirin

          7. History of significant hepatic disease or any other condition that in the judgment of
             the investigator precludes the use of rivaroxaban

          8. Creatinine clearance less than 15 ml per minute

          9. Pre-operative platelet count less than 100 x 109 /L

         10. Need for long-term anticoagulation due to a pre-existing co-morbid condition or due to
             the development of VTE following surgery but prior to randomization

         11. Received anticoagulation post operatively

         12. Bilateral THA/TKA or simultaneous hip and knee arthroplasty

         13. Major surgical procedure within the previous 3 months

         14. Requirement for major surgery post arthroplasty within a 90 day period

         15. Chronic daily aspirin use with dose greater than 100 mg a day

         16. Women of childbearing potential who are not abstinent or do not use effective
             contraception or are breast-feeding throughout the study drug period

         17. Unwilling or unable to give consent

         18. Previous participation in the EPCAT III study

         19. Under 18 years of age

         20. Concomitant use of drugs that are strong inhibitors of P-gp AND CYP3A4 (e.g., systemic
             treatment with ketoconazole, itraconazole, or ritonavir) or strong inducers of P-gp
             AND CYP3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's
             Wort)

         21. Known allergy to food dye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudeep P Shivakumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dalhousie University/Nova Scotia Health Authority</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan L Pleasance, BScN</last_name>
    <phone>902-473-7585</phone>
    <email>susan.pleasance@nshealth.ca</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Sudeep Shivakumar</investigator_full_name>
    <investigator_title>Dr. Sudeep Shivakumar</investigator_title>
  </responsible_party>
  <keyword>total hip and knee arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

